Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 3
Submit an article Journal homepage
228
Views
39
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pegaptanib sodium for the treatment of age-related macular degeneration

Rajendra S Apte Assistant Professor St Louis School of Medicine Washington University, Department of Ophthalmology & Visual Sciences, Barnes Retina Institute, 660 S. Euclid Avenue, PO Box 8096, St Louis, MO 63110, USA +1 314 367 1181; +1 314 362 6793; [email protected]
, MD PhD
Pages 499-508 | Published online: 28 Jan 2008

Citations (39)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Lorenzo Ferro Desideri, Carlo Enrico Traverso & Massimo Nicolò. (2020) Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration. Expert Opinion on Investigational Drugs 29:7, pages 651-658.
Read now
Lorenzo Ferro Desideri, Fabio Barra, Simone Ferrero, Carlo Enrico Traverso & Massimo Nicolò. (2019) Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. Expert Opinion on Biological Therapy 19:8, pages 735-751.
Read now
Anja K Weidemann, Ania A Crawshaw, Emily Byrne & Helen S Young. (2013) Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis. Clinical, Cosmetic and Investigational Dermatology 6, pages 233-244.
Read now
Douglas W Leaman. (2008) Recent progress in oligonucleotide therapeutics: antisense to aptamers. Expert Opinion on Drug Discovery 3:9, pages 997-1009.
Read now

Articles from other publishers (35)

Afsana Sheikh, Shadab Md, Nabil A. Alhakamy & Prashant Kesharwani. (2022) Recent development of aptamer conjugated chitosan nanoparticles as cancer therapeutics. International Journal of Pharmaceutics 620, pages 121751.
Crossref
Afsana Sheikh, Shadab Md & Prashant Kesharwani. (2022) Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer. Biomedicine & Pharmacotherapy 146, pages 112530.
Crossref
Nicole Trier, Paul Hansen & Gunnar Houen. (2019) Peptides, Antibodies, Peptide Antibodies and More. International Journal of Molecular Sciences 20:24, pages 6289.
Crossref
Shira Engelberg, Einat Netzer, Yehuda G. Assaraf & Yoav D. Livney. (2019) Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo. Cell Death & Disease 10:10.
Crossref
Jae Eun Um, Jung Tak Park, Bo Young Nam, Jung Pyo Lee, Jong Ha Jung, Youndong Kim, Seonghun Kim, Jimin Park, Meiyan Wu, Seung Hyeok Han, Tae-Hyun Yoo & Shin-Wook Kang. (2017) Periostin-binding DNA aptamer treatment attenuates renal fibrosis under diabetic conditions. Scientific Reports 7:1.
Crossref
Bo Young Nam, Jung Tak Park, Young Eun Kwon, Jung Pyo Lee, Jong Ha Jung, Youndong Kim, Seonghun Kim, Jimin Park, Jae Eun Um, Meiyan Wu, Seung Hyeok Han, Tae-Hyun Yoo & Shin-Wook Kang. (2017) Periostin-Binding DNA Aptamer Treatment Ameliorates Peritoneal Dialysis-Induced Peritoneal Fibrosis. Molecular Therapy - Nucleic Acids 7, pages 396-407.
Crossref
H.S. Younis, M. Templin, L.O. Whiteley, D. Kornbrust, T.W. Kim & S.P. Henry. 2017. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. A Comprehensive Guide to Toxicology in Nonclinical Drug Development 737 754 .
Marlies Gijs, An Aerts, Nathalie Impens, Sarah Baatout & André Luxen. (2016) Aptamers as radiopharmaceuticals for nuclear imaging and therapy. Nuclear Medicine and Biology 43:4, pages 253-271.
Crossref
David D. Dickey & Paloma H. Giangrande. (2016) Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells. Methods 97, pages 94-103.
Crossref
Vivek K Sharma & Jonathan K Watts. (2015) Oligonucleotide therapeutics: chemistry, delivery and clinical progress. Future Medicinal Chemistry 7:16, pages 2221-2242.
Crossref
Xiaoping Hu, Zhiwei Wang, Hongbing Wu, Wanli Jiang & Rui Hu. (2015) Ras ssDNA aptamer inhibits vascular smooth muscle cell proliferation and migration through MAPK and PI3K pathways. International Journal of Molecular Medicine.
Crossref
William H. Thiel, Kristina W. Thiel, Katie S. Flenker, Tom Bair, Adam J. Dupuy, James O. McNamaraIIII, Francis J. Miller & Paloma H. Giangrande. 2015. RNA Interference. RNA Interference 187 199 .
Hyori Kim, Soomin Yoon & Junho Chung. (2014) In vitro and in vivo application of anti-cotinine antibody and cotinine-conjugated compounds. BMB Reports 47:3, pages 130-134.
Crossref
Miriam Englander & Rishi P. Singh. (2013) Treatment Paradigms in Neovascular AMD. Current Ophthalmology Reports 1:1, pages 12-19.
Crossref
Fabian Tolle & Günter Mayer. (2013) Dressed for success – applying chemistry to modulate aptamer functionality. Chem. Sci. 4:1, pages 60-67.
Crossref
Husam S. Younis, Michael Templin, Lawrence O. Whitely, Douglas Kornbrust, Tae-Won Kim & Scott P. Henry. 2013. A Comprehensive Guide to Toxicology in Preclinical Drug Development. A Comprehensive Guide to Toxicology in Preclinical Drug Development 647 664 .
Theresa Dombi, Kenneth K Kwok & Marla B Sultan. (2012) A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus. BMC Ophthalmology 12:1.
Crossref
Alan F. Cruess, Alan Berger, Kevin Colleaux, Mark Greve, Patricia Harvey, Peter J. Kertes, Thomas Sheidow, Eric Tourville, Geoff Williams & David Wong. (2012) Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration. Canadian Journal of Ophthalmology 47:3, pages 227-235.
Crossref
Richard S. Kaiser, Omesh P. Gupta, Carl D. Regillo, Allen C. Ho, Mitchell S. Fineman, James F. Vander, J. Arch McNamara & Gary C. Brown. (2012) Ranibizumab for Eyes Previously Treated With Pegaptanib or Bevacizumab Without Clinical Response. Ophthalmic Surgery, Lasers and Imaging Retina 43:1, pages 13-19.
Crossref
Fred Reynolds & Kimberly A. Kelly. (2011) Techniques for Molecular Imaging Probe Design. Molecular Imaging 10:6, pages 7290.2011.00003.
Crossref
Jeremy D. Heidel & Mark E. Davis. (2010) Clinical Developments in Nanotechnology for Cancer Therapy. Pharmaceutical Research 28:2, pages 187-199.
Crossref
Jagat R Kanwar, Rajiv R Mohan, Rupinder K Kanwar, Kislay Roy & Raj Bawa. (2010) Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine 5:9, pages 1435-1445.
Crossref
Ulrich Wuellner, Julia I. Gavrilyuk & Carlos F. BarbasIIIIII. (2010) Expanding the Concept of Chemically Programmable Antibodies to RNA Aptamers: Chemically Programmed Biotherapeutics. Angewandte Chemie International Edition 49:34, pages 5934-5937.
Crossref
Ulrich Wuellner, Julia I. Gavrilyuk & Carlos F. BarbasIIIIII. (2010) Expanding the Concept of Chemically Programmable Antibodies to RNA Aptamers: Chemically Programmed Biotherapeutics. Angewandte Chemie 122:34, pages 6070-6073.
Crossref
Günter Mayer & Bernhard Wulffen. 2010. The Chemical Biology of Nucleic Acids. The Chemical Biology of Nucleic Acids 377 400 .
Maximilian C. R. Buff, Florian Schäfer, Bernhard Wulffen, Jens Müller, Bernd Pötzsch, Alexander Heckel & Günter Mayer. (2010) Dependence of aptamer activity on opposed terminal extensions: improvement of light-regulation efficiency. Nucleic Acids Research 38:6, pages 2111-2118.
Crossref
Giuseppe Querques. (2010) Pegaptanib Sodium in the Treatment of Neovascular Age-Related Macular Degeneration. Clinical Medicine Insights: Therapeutics 2, pages CMT.S2393.
Crossref
Douglas B Kell. (2009) Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Medical Genomics 2:1.
Crossref
Y Jian, Z Gao, J Sun, Q Shen, F Feng, Y Jing & C Yang. (2009) RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells. Oncogene 28:47, pages 4201-4211.
Crossref
Julia E. Weigand & Beatrix Suess. (2009) Aptamers and riboswitches: perspectives in biotechnology. Applied Microbiology and Biotechnology 85:2, pages 229-236.
Crossref
Günter Mayer. (2009) The Chemical Biology of Aptamers. Angewandte Chemie International Edition 48:15, pages 2672-2689.
Crossref
Günter Mayer. (2009) Die chemische Biologie von Aptameren. Angewandte Chemie 121:15, pages 2710-2727.
Crossref
Ângela Carneiro, Manuel Falcão, Ana Pirraco, Paula Milheiro-Oliveira, Fernando Falcão-Reis & Raquel Soares. (2009) Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Experimental Eye Research 88:3, pages 522-527.
Crossref
D Mitry, C Schmoll, V Hegde, S Borooah, J Singh & H Bennett. (2008) Use of pegaptanib in the treatment of vitreous haemorrhage in idiopathic retinal vasculitis. Eye 22:11, pages 1449-1450.
Crossref
Gabriele Bergers & Douglas Hanahan. (2008) Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer 8:8, pages 592-603.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.